Oxandrolone (Anavar): High Anabolic Selectivity Research Profile

Research Disclaimer: Oxandrolone is sold exclusively for in-vitro and laboratory research use. Not for unsupervised use. This content does not constitute medical advice.

Oxandrolone (trade name: Anavar, developed by Searle Laboratories in 1964) is a C17α-methylated DHT derivative with an oxygen substituted at C2 of ring A (the "2-oxa" modification). This structural change produces one of the most anabolically selective oral steroids ever developed, with an anabolic:androgenic ratio of approximately 10:1 and an extensive clinical research record spanning burn recovery, pediatric growth disorders, HIV/AIDS wasting, and COPD muscle preservation.

Table of Contents#

1. 2-Oxa Modification: The Key Structural Feature
2. Pharmacokinetics: Oral Bioavailability
3. Anabolic:Androgenic Ratio: Why ~10:1?
4. Mechanism of Extreme Anabolic Selectivity
5. Clinical Research History: Burns, Wasting, Pediatrics
6. Metabolic Effects: Lipids, Glucose, Insulin Sensitivity
7. HPTA Suppression Profile
8. Research Protocols
9. Key References

2-Oxa Modification: The Key Structural Feature#

Oxandrolone structure: 17α-methyl-2-oxa-5α-androstane-3-one-17β-ol

• Based on DHT (5α-reduced) → no 5α-reduction needed → direct AR agonist
• 2-oxa modification: oxygen atom replaces C2 in ring A (a heteroatom substitution)
• C17α-methyl: enables oral bioavailability (resists 17β-HSD metabolism)

Effects of the 2-oxa ring:

1. Cannot be aromatized (DHT-based → aromatase doesn't work)
2. Ring A geometry is altered by the C2 oxygen → affects how ring A interacts with the AR ligand-binding pocket and with 3α-HSD (the enzyme that inactivates DHT via reduction to 3α-androstanediol)
3. Relative resistance to 3α-HSD → less conversion to inactive 3α-metabolite → longer effective t½ at the tissue level
4. The oxygen at C2 may alter electrostatic interactions with certain AR amino acid residues → influences coactivator recruitment

Pharmacokinetics: Oral Bioavailability#

In rodents#

• Oral t½ ~3–6h (faster metabolism)
• Twice or three times daily dosing
• Alternatively: gavage dosing in methylcellulose suspension

Anabolic:Androgenic Ratio: Why ~10:1?#

Oxandrolone's Hershberger assay A:A ratio is approximately 10:1 (levator ani:ventral prostate), compared to testosterone propionate = 1.0:1.0.

This means:

• At a dose that produces a given levator ani weight (anabolic response), oxandrolone causes much less ventral prostate growth than testosterone at the same anabolic dose

Comparison:

Oxandrolone's ~10:1 ratio is the highest among the major anabolic steroids with substantial published evidence — making it the most "anabolically selective" steroidal androgen in common research use.

Mechanism of Extreme Anabolic Selectivity#

How does the 2-oxa ring modification achieve 10× selectivity?

Hypothesis 1: 3α-HSD resistance in androgenic tissues In androgenic tissues (prostate, skin), DHT is inactivated by 3α-HSD → 3α-androstanediol. If oxandrolone is more resistant to 3α-HSD than DHT (due to the C2 oxygen steric effect), less inactivation occurs — but this would predict HIGHER androgenicity, not lower. So this mechanism alone doesn't explain it.

Hypothesis 2: Tissue-specific coactivator expression The 2-oxa ring changes the AR conformation subtly, which alters which coactivators are recruited:

• Muscle cells express SRC-3/AIB1 prominently → effectively recruits these coactivators for strong ARE-driven anabolic gene expression
• Prostate cells express SRC-1 prominently → less efficiently recruits with the 2-oxa-modified AR conformation
• Net: more efficient anabolic transcription in muscle vs. androgenic transcription in prostate

Hypothesis 3: Differential AR expression levels Levator ani has very high AR expression → any AR agonist can saturate AR and produce maximal response. Ventral prostate also has high AR, but the 2-oxa geometry may make oxandrolone require more receptor occupancy for equivalent transcriptional output → apparent selectivity at the tissue scale.

Most current consensus: a combination of hypothesis 2 (coactivator interaction specificity) and intrinsic compound stability differences is most consistent with the data. The exact mechanism remains incompletely characterized.

Clinical Research History: Burns, Wasting, Pediatrics#

Oxandrolone has the most extensive clinical research record of any anabolic steroid:

Burn recovery#

• Major burns cause profound muscle wasting (catabolic response)
• Oxandrolone 0.1 mg/kg twice daily (pediatric) or 20 mg/day (adult) → improved lean body mass, reduced time to wound healing, decreased hospital stay
• Mechanism: AR-driven muscle protein synthesis + reduced cortisol-driven catabolism (no direct GR antagonism, but anti-catabolic via mTOR/Akt pathway)
• Published RCTs from Galveston Shriners Hospital (Herndon DS group): pediatric burn patients, outcomes improved with oxandrolone treatment lasting months post-injury

HIV/AIDS wasting syndrome#

• HIV-associated weight loss (wasting): AR agonism → muscle preservation
• Oxandrolone 20 mg/day in HIV+ men → significant lean mass gain, improved functional status
• FDA-approved indication: weight gain after weight loss from surgery, infection, trauma, failure to gain

Pediatric short stature#

• Turner syndrome, constitutional growth delay: oxandrolone (very low doses, 0.05 mg/kg/day) promotes linear growth
• Mechanism: IGF-1 stimulation via AR in liver and growth plate chondrocytes
• Critical concern: bone age advancement — oxandrolone at higher doses advances bone age faster than linear height → net negative growth in excess

COPD and sarcopenia models#

• Oxandrolone in COPD: preserves muscle mass during pulmonary rehabilitation
• Sarcopenia in elderly males: modest anabolic effect on lean mass with minimal androgenic side effects (relevant given prostate risk in older males)

Metabolic Effects: Lipids, Glucose, Insulin Sensitivity#

Lipid effects#

All C17α-alkylated oral anabolic steroids have adverse lipid effects compared to injectable androgens:

• Oral anabolics → hepatic first-pass → direct hepatic AR activation → reduced hepatic HDL-ApoA1 production → decreased HDL cholesterol (HDL-C)
• Oxandrolone: HDL-C decreases ~50–70% from baseline at therapeutic doses (20 mg/day for 12 weeks)
• LDL-C: modest increase (less than HDL-C decrease)

This is a significant concern for long-term therapeutic use and a research endpoint in cardiac risk studies.

Insulin sensitivity#

Unlike some androgens (which can worsen insulin resistance at high doses), oxandrolone at therapeutic doses has been associated with improved or neutral insulin sensitivity:

• Burn patients: oxandrolone → improved insulin sensitivity in the context of post-burn hyperglycemia
• HIV wasting: neutral or positive insulin sensitivity effects
• Mechanism: muscle mass gain → more insulin-sensitive glucose disposal capacity

HPTA Suppression Profile#

At standard therapeutic doses (20 mg/day in humans):

• LH and FSH: moderate suppression (~50–70%)
• Does not achieve complete gonadotropin suppression like injectable androgens at anabolic doses
• HPTA recovery after cessation: relatively fast (oral, short t½, limited suppression depth)

In rodents at equivalent anabolic doses:

• LH/FSH: moderate suppression
• Testicular weight: slight decrease but not severe
• Complete recovery within 4–6 weeks post-cessation

Research Protocols#

Wasting disease model (surgical catabolic stress, rats)#

Pediatric burn model (rodent scald)#

Key References#

1. Herndon DN, et al. (2009). "Reversal of catabolism by beta-blockade after severe burns." New England Journal of Medicine, 345(17):1223–1229.

2. Fox M, et al. (1962). "The clinical use of oxandrolone in growth disorders." Journal of Pediatrics, 61:867–876.

3. Kicman AT. (2008). "Pharmacology of anabolic steroids." British Journal of Pharmacology, 154(3):502–521.

4. Orr R & Singh MF. (2004). "The anabolic androgenic steroid oxandrolone in the treatment of wasting and catabolic disorders: review of efficacy and safety." Drugs, 64(7):725–750.

Research Use Only: Oxandrolone is sold exclusively for in-vitro research and laboratory use. Not for unsupervised use. JuicedPharma does not provide medical advice.

Published by JuicedPharma Research Team · September 2026 · Category: Research Protocols & Science